Research programme: targeted MRI contrast agents - Starpharma
Latest Information Update: 13 Apr 2011
Price :
$50 *
At a glance
- Originator Starpharma
- Developer Baker IDI; National Cancer Institute (USA); Starpharma
- Class Contrast media
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Ovarian cancer
Most Recent Events
- 29 Feb 2008 Early research in Cardiovascular disorders in Australia (Parenteral)
- 29 Feb 2008 Early research in Ovarian cancer in USA (Parenteral)